Ann Arbor, MIDiapin Therapeutics, LLC., a company dedicated to the development of treatments for type 2 diabetes and cardiovascular disease, announced today the awarding of a Phase 1 SBIR grant entitled “D - Cardiovascular disease - Document - PDFSEARCH.IO

First Page	Meta Content
	Ann Arbor, MIDiapin Therapeutics, LLC., a company dedicated to the development of treatments for type 2 diabetes and cardiovascular disease, announced today the awarding of a Phase 1 SBIR grant entitled “D Add to Reading List Document Date: 2015-03-10 10:24:42 Open Document File Size: 68,97 KB Share Result on Facebook

Ann Arbor, MIDiapin Therapeutics, LLC., a company dedicated to the development of treatments for type 2 diabetes and cardiovascular disease, announced today the awarding of a Phase 1 SBIR grant entitled “DAdd to Reading List